Trial Profile
A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) in comparison to Metvix in the treatment of non-aggressive basal cell carcinoma (BCC) with photodynamic therapy (PDT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2022
Price :
$35
*
At a glance
- Drugs Aminolevulinic acid (Primary) ; Methyl aminolevulinate
- Indications Basal cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Biofrontera Bioscience GmbH
- 12 Feb 2018 Primary endpoint (Patient complete response rate )has been met, according to the results published in the British Journal of Dermatology
- 12 Feb 2018 Results published in the British Journal of Dermatology
- 15 Apr 2016 Status changed from active, no longer recruiting to completed, as reported in a Biofrontera AG media release.